MK-8507 / Merck (MSD)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK-8507 / Merck (MSD)
NCT02174159: Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)

Completed
1
18
NA
Ulonivirine, MK-8507
Merck Sharp & Dohme LLC
HIV-1 Infection
07/15
07/15
MK-8507-014, NCT05093972: Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment

Not yet recruiting
1
22
NA
Ulonivirine, MK-8507
Merck Sharp & Dohme LLC
Hepatic Insufficiency
09/25
09/25

Download Options